Loading clinical trials...

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy Subjects

NCT02103894•Molecular NeuroImaging

View on ClinicalTrials.gov

Summary

The goal of this study is to assess \[18F\]MNI-777 PET imaging as a tool to detect tau pathology in the brain of individuals who carry a clinical diagnosis of a tauopathy, including: Alzheimer's Disease (AD),Parkinson's disease (PD) Progressive Supranuclear Palsy (PSP), chronic traumatic encephalopathy (CTE) and Frontal Temporal Dementia (FTD) and age- and gender-matched healthy subjects.

Eligibility

Age

18 - 85 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•For all subjects:
•Written informed consent or assent is obtained.
•Willing and able to cooperate with study procedures.
•For females, non-child bearing potential or negative urine pregnancy test on day of \[18F\]MNI-777 injection.
•Alzheimer Disease subjects:
•The participant is 50 years or older.
•Participants have a clinical diagnosis of Alzheimer's disease based on National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria (McKann, 1984)
•Modified Hachinski Ischemia Scale score of ≤ 4.
•Parkinson's Disease subjects:
•The participant is 30 years or older.
+17 more criteria

Exclusion Criteria

•All subjects will be excluded from participation for the following reasons:
•The subject has a clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness.
•The subject has any disorder that may interfere with drug absorption distribution, metabolism, or excretion (including gastrointestinal surgery).
•The subject has evidence of a structural lesion on MRI that may interfere with interpretation of PET imaging.
•The subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease.
•The subject has participated in another clinical study within the previous 30 days.
•Pregnancy or women who are nursing or breastfeeding

Locations (1)

Molecular NeuroImaging, LLC

New Haven, Connecticut, United States

Key Dates

Start Date

February 1, 2014

Primary Completion Date

August 1, 2016

Completion Date

September 1, 2016

Last Updated

December 16, 2016

Enrollment

ACTUAL participants

Conditions

Alzheimer's Disease (AD)Parkinson's Disease (PD)Chronic Traumatic Encephalopathy (CTE)Progressive Supranuclear Palsy (PSP)Frontal Temporal Dementia (FTD)Pick's DiseaseTauopathies

Interventions

[18F]T807 ([18F]MNI-777)

DRUG

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

NCT07310264

Healthy Volunteers (HV)Parkinson's Disease (PD)

View study

RECRUITINGPHASE3

Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function

NCT07422857

Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 16, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects

Inclusion Criteria

Exclusion Criteria

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function

LIFUS For Neurological Disorders

Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease

A Phase 2 Study to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MRS in Patients With Early, Untreated Parkinson's Disease

Novel DBS Device in Parkinson's Disease